Septal Reduction Using Transvenous Intramyocardial Cerclage Radiofrequency Ablation: Preclinical Feasibility
Eun-Seok Shin, Min-Ku Chon, Eun Jung Jun, Yong-Hyun Park, Sang-Hyun Lee, Jeong-Su Kim, Dong-Hun Shin, Soo-Yong Lee, Min Soo Cho, Seung-Whan Lee, Markus Reinthaler, Jai-Wun Park, Gi-Byung Nam, Robert J Lederman, Yonghyun Won, June-Hong Kim, Eun-Seok Shin, Min-Ku Chon, Eun Jung Jun, Yong-Hyun Park, Sang-Hyun Lee, Jeong-Su Kim, Dong-Hun Shin, Soo-Yong Lee, Min Soo Cho, Seung-Whan Lee, Markus Reinthaler, Jai-Wun Park, Gi-Byung Nam, Robert J Lederman, Yonghyun Won, June-Hong Kim
Abstract
Debulking of left ventricular septal mass is typically accomplished using surgical myectomy, which is morbid, or using transcoronary alcohol septal ablation, which can result in geographic miss and occasional catastrophic nontarget coronary injury. The authors developed and tested operational parameters in vitro and vivo for a device to accomplish transvenous intraseptal radiofrequency ablation to reduce ventricular septal mass using a technique derived from mitral cerclage, which the authors call cerclage ablation. Cerclage ablation appeared feasible in vitro and safe and effective in vivo. Cerclage ablation is an attractive new approach to debulk the interventricular septum in obstructive hypertrophic cardiomyopathy. These data support clinical investigation.
Keywords: AV, atrioventricular; CT, computed tomography; HCM, hypertrophic cardiomyopathy; RF, radiofrequency; TTE, transthoracic echocardiography; echocardiography; hypertrophic cardiomyopathy; mitral cerclage; radiofrequency ablation; ventricular septum.
Conflict of interest statement
This study was supported by Research and Development grant S2773417 from the Korean Ministry of Small and Medium Enterprise and Startups. Tau-PNU Medical provided the prototype ablation catheters. Dr. J.-W. Park is a medical consultant for Tau-PNU Medical. Drs. J.-H. Kim and Nam are coinventors on patents for devices for mitral loop cerclage ablation. Dr. J.-H Kim is a stockholder of Tau-PNU Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2020 The Authors.
Figures
References
- Elliott P., Gimeno J., Tomé M., McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J. 2006;27:3073.
- Maron M.S., Olivotto I., Betocchi S. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.
- Gimeno J.R., Tome-Esteban M., Lofiego C. Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J. 2009;30:2599–2605.
- Elliott P.M., Anastasakis A., Borger M.A. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J. 2014;35:2733–2779.
- Armistead S., Williams B. Hypertrophic obstructive cardiomyopathy. The use of a diathermy loop for septal resection. J Cardiovasc Surg. 1984;25:185–186.
- Smedira N.G., Lytle B.W., Lever H.M. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85:127–133.
- Iacovoni A., Spirito P., Simon C. A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy. Eur Heart J. 2012;33:2080–2087.
- Kim L.K., Swaminathan R.V., Looser P. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. JAMA Cardiol. 2016;1:324–332.
- Chan W., Williams L., Kotowycz M.A. Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Can J Cardiol. 2014;30:912–919.
- Alam M., Dokainish H., Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol. 2006;19:319–327.
- Liebregts M., Faber L., Jensen M.K. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol Intv. 2017;10:1134–1143.
- Liebregts M., Vriesendorp P.A., Ten Berg J.M. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement. J Am Coll Cardiol. 2017;70:481–488.
- Liu L., Li J., Zuo L. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2018;72:1898–1909.
- He G., Sun C., Zhang X. Echocardiography-guided percutaneous per-ventricular laser ablation of ventricular septum: in vivo study in a canine model. Lasers Med Sci. 2016;31:645–651.
- Kim J.H., Kocaturk O., Ozturk C. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. 2009;54:638–651.
- Chon M.-K., Jung S.-M., Lee S.Y. TCT-18 Novel concept of catheter-based treatment for tricuspid regurgitation (Cerclage-TR block): a preliminary animal experiment in a swine model (abstr) J Am Coll Cardiol. 2018;72 Suppl:B8.
- Cho M.S., Chon M.K., Choi J.H. Cerclage parahisian septal pacing through the septal perforator branch of the great cardiac vein: bedside-to-bench development of a novel technique and lead. J Heart Rhythm. 2019;16:1834–1840.
- Park Y.-H., Chon M.-K., Lederman R.J. Mitral loop cerclage annuloplasty for secondary mitral regurgitation: first human results. J Am Coll Cardiol Intv. 2017;10:597–610.
- Mulier P.M.J., Hoey M.F., inventors; DUTHLER REED A, Medtronic Inc, assignee . US patent 5431649A; 1997. Method and apparatus for R-F ablation.
- Rydell M.A., inventor; Everest Medical Corp, assignee . CA patent 2037242A1; 1992. RF ablation catheter.
- Imran M.A., Pomeranz M.L., inventors; Boston Scientific Corp, Boston Scientific Scimed, assignees . US patent 5348554A; 1994. Catheter for RF ablation with cooled electrode.
- Müssigbrodt A., Grothoff M., Dinov B. Irrigated tip catheters for radiofrequency ablation in ventricular tachycardia. Biomed Res Int. 2015;2015:389294.
- Cooper R.M., Shahzad A., Hasleton J. Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation. Ep Europace. 2016;18:113–120.
- Crossen K., Jones M., Erikson C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2016;13:1885–1890.
- Lawrenz T., Borchert B., Leuner C. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients. J Am Coll Cardiol. 2011;57:572–576.
- Poon S.S., Cooper R.M., Gupta D. Endocardial radiofrequency septal ablation—a new option for non-surgical septal reduction in patients with hypertrophic obstructive cardiomyopathy (HOCM)?: a systematic review of clinical studies. Int J Cardiol. 2016;222:772–774.
- Sreeram N., Emmel M., de Giovanni J.V. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children. J Am Coll Cardiol. 2011;58:2501–2510.
- Yang H., Yang Y., Xue Y., Luo S. Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis. Clinical Cardiology. 2020;43:450–458.
- Kaye G.C., Linker N.J., Marwick T.H. Effect of right ventricular pacing lead site on left ventricular function in patients with high-grade atrioventricular block: results of the Protect-Pace study. Eur Heart J. 2015;36:856–862.
- Ong S.L., Gravante G., Metcalfe M.S., Dennison A.R. History, ethics, advantages and limitations of experimental models for hepatic ablation. World J Gastroenterol. 2013;19:147–154.
Source: PubMed